A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(26 sites)

United States

University of Michigan, Ann Arbor, Michigan

France

Centre Hospitalier Universitaire d'Angers, Angers, Cedex 09

Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital La Conception, Marseille, Europe

Hopital Louis Pradel, Bron

APHP - Hôpital Bicêtre, Le Kremlin-Bicêtre

Centre Hospitalier Universitaire De Lille, Lille

Hopital Haut-Leveque, Pessac

Georgia

Ltd Tbilisi Central Hospital, Tbilisi, Europe

National Institute of Endocrinology, Tbilisi, Europe

Multiprofile Clinic Consilium Medulla Ltd, Tbilisi, Europe

Ltd Aversi Clinic, Tbilisi

Hungary

Semmelweis Egyetem, Belgyogyaszati es Onkologiai Klinika, Budapest

Debreceni Egyetem Klinikai Kozpont, Debrecen

University Hospital of Pecs, Pécs

Italy

Azienda Ospedale Università di Padova, Padova, Europe

Azienda Ospedaliero-Universitaria Pisana, Pisa, Europe

AOU Policlinico G. Martino, Messina

Azienda Ospedaliera Universitaria Sant'Andrea, Rome

AOU Citta della Salute e della Scienza di Torino, Torino

Romania

Institutul National de Endocrinologie "C.I. Parhon", Bucharest

Spitalul Clinic Judetean de Urgenta Cluj-Napoca, Clju-Napoca

Spitalul Clinic Judetean Mures, Mures

Spain

Hospital de la Santa Creu i de Sant Pau, Barcelona

Hospital Universitario Ramon y Cajal, Madrid

United Kingdom

Northern Care Alliance, North Manchester General Hospital, Manchester, Europe

University of Birmingham Institute of Metabolism and Systems Research, Birmingham